On January 23, 2025, the District Court for the District of New Jersey entered a Consent Judgment and Injunction in view of a settlement agreement between Amgen and Celltrion resolving the BPCIA ...

Amgen Inc. upgraded to cautious Buy: pipeline growth drivers, margin upside, and risk/reward near lows. Click for this AMGN ...

Xgeva and Prolia are two drugs Amgen investors need to keep an eye on. Thanks to label expansion that permitted wider use of the drugs, they've been Amgen's fastest-growing products this past year.

Aug 13 (Reuters) - Amgen (AMGN.O), opens new tab has sued Samsung's biologics unit (207940.KS), opens new tab in New Jersey federal court over its proposed biosimilar versions of Amgen's blockbuster ...

Amgen (AMGN) stock is at an interesting point right now. If you bet on it, you are betting on a company that's growing reasonably, is sustaining good cash flow and margin, has a low-debt to market ...

Ozempic, Mounjaro, Wegovy, or Zepbound? This ETF Holds Them All Amgen (NASDAQ:AMGN) executives used a Jefferies investor ...

Generic and biosimilar manufacturer Sandoz AG (OTC:SDZNY) (OTC:SDZXF) reached an agreement on Tuesday with Amgen Inc (NASDAQ:AMGN) to resolve all patent litigation related to its U.S. denosumab ...

Biocon Biologics agreed to a settlement-and-license agreement with Amgen that will permit it to market drugs in the United States that are biosimilars to Amgen's Prolia and Xgeva. Both medications use ...

Sandoz shared that it has reached agreement with Amgen to resolve all patent disputes between the two companies relating to the Food and Drug Administration approved Sandoz denosumab biosimilars.

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

Guggenheim trimmed its price target (PT) on Amgen (NASDAQ:AMGN) to $340 from $351 on Monday, May 4, while maintaining a Neutral rating. The revision follows the biotech’s Q1 2026 earnings release and ...

On September 30, 2025, the U.S. District Court for the District of New Jersey entered a Consent Judgment and Injunction resolving the denosumab BPCIA litigation between Amgen, Inc. (“Amgen”) and ...